



آغا خان یونیورسٹی

THE AGA KHAN UNIVERSITY

FONDATION
SANOFIESPO(R)

Organised by

Section of Paediatric Oncology
Department of Oncology
Aga Khan University, Pakistan

Information

Syed Emad Uddin
021 3486 1969
syed.emad@aku.edu

Paediatric Neuro Oncology Virtual Lecture Series by International Faculty

Targeted Therapy Trials in High Grade Gliomas

Moderator

Dr Naureen Mushtaq
Associate Professor, Section Head, Paediatric Oncology
Aga Khan University



Tuesday, 24th August 2021, | 5:00-6:00 pm (PKT GMT +5)

Zoom link:

<https://aku-edu.zoom.us/j/93328199764>

Meeting Passcode: **950333**

Target audience

This lecture series is targeted towards Paediatric Oncologists, Neurosurgeons, Radiologists, Histopathologist, Radiation Oncologist and Nurses involved in the diagnosis and care of Paediatric Brain Tumours.

Objectives of the presentation:

- Discuss what we mean by targeted therapy
- Evaluate the methods used to identify targets in paediatric HGG and the potential role of targeted therapy for children with HGG and other brain tumours
- Discuss the challenges that targeted therapy approaches face in resource constrained environments

Registration for the lecture (Mandatory)

[Click Here](#)

International Faculty Speaker

Dr Mark Kieran, MD, PhD

Clinical Development Lead, Paediatric Oncology,
Bristol Myers Squibb, Princeton Pike, NJ
Former Director of Paediatric Neuro-Oncology at the
Dana-Farber Boston Children's Cancer and Blood
Disorders Center, Affiliates of Harvard Medical School

Dr. Mark Kieran is Senior Director of Pediatric Oncology in Global Drug Development at Bristol Myers Squibb. He received his first PhD in 1983 from the University of Alberta and his MD in 1986 from the University of Calgary. After a post-doc in molecular biology at the Pasteur Institute in Paris and a paediatric residency at McGill University in Montreal, he completed a fellowship in paediatric haematology /oncology as well as a second post-doc in signal transduction at Boston Children's Hospital. Dr. Kieran became Director of Pediatric Medical Neuro-Oncology at Dana-Farber Boston Children's Cancer and Blood Disorders Center in 1999. Dr. Kieran's primary research interest was the genomic identification of mutations and development of new targeted therapies for children with brain tumors. He has a particular focus on tumours of glial origin and the identification of the biology that leads to their growth. His laboratory focused on the immune microenvironment of tumours while the clinical program centered on the initiation of early phase trials for brain tumours based on the improved understanding of their biology and incorporation of personalized approaches such as targeted therapies, biologic therapies, immune therapy, and gene therapy.

The Aga Khan University is accredited by the

Accreditation Council for Continuing Medical Education (ACCME)

The ACCME designates this live educational activity for a maximum of 1.00 credit hours of AMA PRA category 1 credit™
The faculty, staff and any individual connected to this activity confirms that this activity do not have any financial relationship with proprietary entities, producing, marketing, re-selling or distributing healthcare goods or services consumed or used on patients.

